HC Wainwright Analysts Decrease Earnings Estimates for ORKA

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Investment analysts at HC Wainwright lowered their FY2024 EPS estimates for Oruka Therapeutics in a research note issued on Monday, November 25th. HC Wainwright analyst M. Kapoor now forecasts that the company will earn ($2.24) per share for the year, down from their previous forecast of ($1.56). HC Wainwright has a "Buy" rating and a $45.00 price target on the stock. The consensus estimate for Oruka Therapeutics' current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Oruka Therapeutics' Q4 2024 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.98) EPS.

Other research analysts have also issued reports about the company. Leerink Partners assumed coverage on Oruka Therapeutics in a research note on Tuesday, September 17th. They set an "outperform" rating and a $44.00 price objective for the company. Leerink Partnrs raised shares of Oruka Therapeutics to a "strong-buy" rating in a report on Tuesday, September 17th. TD Cowen assumed coverage on shares of Oruka Therapeutics in a research report on Monday, September 16th. They issued a "buy" rating on the stock. Wedbush reaffirmed an "outperform" rating and set a $40.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Finally, Lifesci Capital assumed coverage on Oruka Therapeutics in a report on Monday, September 16th. They issued an "outperform" rating and a $41.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $43.17.

Oruka Therapeutics Stock Up 8.4 %

Shares of ORKA traded up $1.57 during mid-day trading on Wednesday, reaching $20.26. The company had a trading volume of 51,265 shares, compared to its average volume of 67,913. The stock's 50-day moving average price is $25.86. The stock has a market cap of $709.08 million, a P/E ratio of -2.99 and a beta of 0.87. Oruka Therapeutics has a twelve month low of $18.20 and a twelve month high of $53.88.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. FMR LLC acquired a new position in shares of Oruka Therapeutics during the third quarter valued at $114,763,000. RTW Investments LP bought a new stake in Oruka Therapeutics during the 3rd quarter worth about $45,359,000. Franklin Resources Inc. acquired a new position in Oruka Therapeutics during the 3rd quarter valued at about $17,661,000. Braidwell LP bought a new position in shares of Oruka Therapeutics in the 3rd quarter valued at about $12,640,000. Finally, Great Point Partners LLC acquired a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $12,614,000. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.